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Background. Gonadotropin releasing hormone analogs (GnRHas) are standard of care for central precocious puberty (CPP). The
histrelin subcutaneous implant is safe and eﬀective in the treatment of CPP for one year. Objective. The study evaluates a second
year of therapy in children with CPP who received a new implant after one year of treatment. Methods. A prospective one-year
study following an initial 12-month treatment period was conducted. Results. Thirty-one patients (29 girls) aged 7.7 ± 1.5 years
receivedasecondimplant.Eighteenwerena¨ ıvetoGnRHatherapyatﬁrstimplantation.PeakLHdeclinedfrom0.92±0.58mIU/mL
at 12 months to 0.51 ± 0.33mIU/mL at 24 months (P<.0001) in na¨ ıve subjects, and from 0.74 ± 0.50mIU/mL at 12 months to
0.45 ± 0.35mIU/mL at 24 months (P = .0081) in previously treated subjects. Predicted adult height increased by 5.1cm at 24
months (P = .0001). Minor implant site reactions occurred in 61%, while minor diﬃculties with explantation occurred in 32.2%
of subjects. Conclusion. The histrelin implant demonstrates profound hypothalamic-pituitary-gonadal axis suppression when a
new implant is placed for a second year of treatment. Prospective follow-up of this therapeutic modality for the treatment of CPP
is needed.
Copyright © 2009 Samar Rahhal et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Central precocious puberty (CPP) is deﬁned as activation of
the hypothalamic-pituitary-gonadal (HPG) axis before the
age of 8 years in Caucasian girls and 7.5 years in African
American girls, and before the age of 9 years in boys [1].
Treatment is often initiated with the goal of preserving
ﬁnal adult height. Gonadotropin releasing hormone analogs
(GnRHa) have been the cornerstone of treatment of CPP
for more than 20 years [2]. A depot form of GnRHa is
traditionally used in the US and is administered as a monthly
injection. Although known to be safe and eﬀective [3–5],
the need for intramuscular injections may be bothersome to
patients and adversely aﬀect compliance.
A one-year subcutaneous histrelin implant has emerged
as an alternative approach for the treatmentof CPP. Histrelin
isaGnRHawhichis150timesmorepotentthanendogenous
GnRH. The implant is a ﬂexible, non-biodegradable device
that contains histrelin acetate and is inserted subcutaneously
using a trocar. The microporous walls allow histrelin to
diﬀuse at a rate of approximately 65mcg/day. A pilot study
of 11 girls with CPP showed that the implant eﬀectively
suppressedtheHPGaxis[6].ThiswasfollowedbyaphaseIII
prospective trial involving 36 children which demonstrated2 International Journal of Pediatric Endocrinology
Table 1: Patient characteristics at month 12 when the second implant was placed.
GnRHa na¨ ıve (N = 18) GnRHA pretreated (N = 13) All patients (N = 31)
Age (years) 8.0 ±1.4 years 9.6 ±1.3 years 8.7 ±1.6 years (range, 5–11)
Sex 18 Girls (100.0%) 11 Girls (84.6%) 29 Girls (93.5%)
0 Boys 2 Boys (15.4%) 2 Boys (6.5%)
Weight (Kg) 39.4 ±9.7 51.3. ± 12.9 44.4 ±12.5 (range, 24–72)
Height SDS (cm) 1.7 ±1.14 1.2 ±1.02 1.5 ±1.10
BMI (%) 88.3 ±17.69 3 .6 ±10.19 0 .6 ±14.9
BMI = body mass index.
safety and eﬃcacy of the implant for one year [7]. Whether
a second year of therapy with a new implant would have
similar results is unknown. Thus, the objective of this study
was to determine safety and eﬃcacy of a second year of
therapy with a new implant for the treatment of CPP.
2. Methods
2.1. Subjects. Patients from nine US medical centers who
completed the one-year phase III trial were oﬀered the
option to have a second implant placed. Institutional review
board approval was obtained at each site. Informed consent
was obtained from parents or legal guardians, and assent
from all children greater than 7 years of age. Inclusion
criteria included patients in whom the decision was made to
continue with GnRHa therapy.
2.2. Study Design. This was a one-year multicenter prospec-
tive open label trial. At all sites, a pediatric surgeon removed
the ﬁrst implant and inserted the second during the same
procedure, using a standardized trocar device. The type of
anesthesia used varied according to site, and included local
anesthesia, conscious sedation, or general anesthesia. All
implants contained 50mg of histrelin. Clinic visits occurred
every 6 months. Height and weight were measured at
every visit and annualized growth velocity was determined.
GnRHa stimulation tests were performed at 1, 6, and 12
months after placement of the second implant. They were
performed using a dose of 20mcg/kg of aqueous leuprolide
acetate and measuring LH and FSH at baseline, 30, and 60
minutes after GnRHa. Gonadotropin levels were measured
by immunochemiluminometric assay (Esoterix, Calabasas
Hills, Calif, USA). Stimulated levels of LH < 4mIU/mLand
FSH<2.5mIU/mL were considered suppressed (prepubertal
references values; LH 0.02–3, FSH 1.0–4.2 in girls, 0.26–
3.0 in boys). Estradiol and testosterone were measured
by radioimmunoassay (Esoterix) at baseline only. Levels
below 20pg/mL (73.42pmol/L) for estradiol and 30ng/dl
(0.69nmol/L) for testosterone were considered suppressed
(prepubertal reference ranges; estradiol <15pg/mL, testos-
terone 3–10ng/dL) . Histrelin levels were measured at 1,
6, and 12 months after placement of the second implant.
Bone age radiographs were obtained annually and were
centrally read (Lifespan Health Research Center, Kettering,
Ohio, USA). Predicted adult heights were determined using
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Figure 1: Peak LH in na¨ ıve and previously treated subjects from
baseline through Month 24.
the Bayley-Pinneau method [8], using the average rather
than accelerated tables.
2.3. Statistics. Summary statistics were performed to derive
baseline characteristics. Data are expressed as mean ±
standard deviation. All statistical tests were conducted using
the student’s paired t-test. All analysis and computations
were performed using SAS version 9.1.3 (SAS Institute,
Cary, NC, USA) on the Microsoft Windows XP platform
(Richmond, Calif, USA).
3. Results
3.1.SubjectCharacteristics. Thirtyonepatients(29girls)had
a second implant placed. Of these, 18 had been na¨ ıve to
GnRHa treatment prior to placement of the ﬁrst implant
and 12 had been previously treated. Patient characteristics
are summarized in Table 1.
3.2. Hormonal Assessments. Peak LH in response to GnRHa
stimulation remained suppressed in all subjects throughout
the study period (Figure 1). It decreased from 0.92 ±
0.58mIU/mL at 12 months to 0.51 ± 0.33mIU/mL at 24
months (P<. 0001) in the na¨ ıve group, and from 0.74 ±
0.50mIU/mL at 12 months to 0.45 ± 0.35mIU/mL atInternational Journal of Pediatric Endocrinology 3
Mean histrelin concentrations (ng/mL) results over
24-month period
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Figure 2: Histrelin levels throughout the 2 years of therapy.
24 months (P = .0081) in previously treated subjects. Peak
FSH in response to GnRHa stimulation at 24 months was
not diﬀerent than at 12 months and remained suppressed
at 2.45 ± 1.12mIU/mL (na¨ ıve) and 2.40 ± 1.11mIU/mL
(previously treated). Estradiol levels remained suppressed
throughout the second year of therapy. Testosterone levels
in the two boys at 24 months were 6.8ng/dL and 13ng/dL,
respectively. Histrelin levels were detectable throughout the
second year of therapy and are shown in Figure 2.
3.3. Radiographic Studies and Growth Parameters. The aver-
age bone age to chronological age ratio decreased signiﬁ-
cantly in all patients from 1.29 at the time of the second
implant to 1.23 at 24 months (P<. 0001) (Figure 3). No
diﬀerence in growth velocity SDS was seen at 24 months
compared to 12 months in the na¨ ıve patients. In contrast,
the growth velocity SDS decreased from −1.50 ± 2.70 at 12
monthsto−2.52±2.68at24monthsinthepreviouslytreated
patients (P = .005). One patient in the na¨ ıve group was
started on growth hormone because of signiﬁcant slowing of
growth. As shown in Figure 4, average predicted adult height
increased in both groups of girls at 24 months relative to
baseline,resultingina5.1cmincreaseinthegroupasawhole
after two years of treatment, (P<. 0001). Mean predicted
adult height for the two boys was 165.6cm at baseline and
163.7cm at 24 months (P = .84). BMI percentiles decreased
in all patients from 89.9 ±12.5% at baseline to 88.0 ±19.6%
at 24 months (P<. 001). Tanner staging did not signiﬁcantly
change over the course of the year. Testicular volume was 3–
6mLinoneboyand6–10mLintheotherat24months,both
o fw h i c hw e r en o td i ﬀerent from 12 months.
3.4.Safety. Nineteenpatients(61%)reportedminorimplant
site reactions, (e.g., bruising or pain) immediately after
implant replacement. These were self-resolving and of brief
duration. One patient developed a keloid. There were
no cases of spontaneous implant extrusion or infection.
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Figure 3: Ratio of bone age to chronological age at baseline, 12 and
24 months in all subjects.
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Figure 4: Predicted adult height at baseline, 12 and 24 months in
both groups of subjects. ∗P<. 02 compared to baseline, †P<. 01
compared to 12 months.
12 months, 8 patients (22.2%) had implant breakage on
removal and 2 (5.6%) required ultrasound localization prior
to explantation. At 24 months, 5 patients (16.1%) had
implant breakage on removal and 3 cases (9.6%) required
ultrasound localization.
4. Discussion
The treatment for CPP in the US has traditionally involved
intramuscular monthly injections of leuprolide acetate.
While a three-month depot leuprolide is available, it has not
been adequately studied in children and failed to demon-
strate equivalent short-term HPG axis suppression when
compared to monthly injections [9]. Although experience is
limited,thehistrelinacetateimplantappearstobeanexciting4 International Journal of Pediatric Endocrinology
novel therapy for CPP that obviates the need for injections.
Following placement of a new implant at 12 months, HPG
axis suppression was maintained in all patients throughout
a second year of therapy. In addition, the rate of skeletal
maturation slowed signiﬁcantly and predicted adult heights
improved after 24 months compared to baseline.
In terms of safety, the implant was well tolerated overall.
Implant site reactions were mild, and minor diﬃculties with
implant removal were reported either at 12 or 24 months
in ∼20% of patients. These involved implant breakage and
the need for ultrasound to localize the implant. While the
implants were not found to be broken in situ, some broke
on removal and this made the explant process more diﬃcult
and in some cases more time consuming. Implant breakage
may be related to surgical technique and with improved
experience, complications may be avoidable. Although no
adverse events related to anesthesia have been reported
in patients treated with the implant, the inherent risks
of conscious sedation and general anesthesia in particular
should be taken into consideration when these methods are
used.
The main theoretical concern with the histrelin implant
is the potential for adverse eﬀects on growth, body com-
position, and the reproductive system from the even more
profound HPG axis suppression than that seen with tradi-
tional therapy. Results from this study suggest that a decline
in stimulated LH might occur in each successive year of
treatment with this device. While this may raise concern
regarding growth while on the implant, a recent study
actually suggests that increased suppression of the HPG axis
in children with CPP may result in improved growth velocity
[10]. In our study, the growth velocity SDS did not change
signiﬁcantly in year 2 in the na¨ ıve group, but it did decline
in the previously treated patients. However, this was likely
related to the relatively advanced bone ages in this group
of children at the time that the second implant was placed.
Despite this, an improvement in predicted adult heights was
seen in both groups of patients. Also reassuring was the
small yet signiﬁcant decrease in BMI noted at 24 months
compared with 12 months. Finally, 4 of the 5 patients who
did not have a second implant placed at 12 months returned
for stimulated LH measurements at 13 months. HPG axis
recovery was noted in all 4 subjects by that time. In addition,
histrelin levels were undetectable by 13 months. Information
from patients on therapy for longer than one year will be
needed to determine whether timing of HPG axis recovery
will be diﬀerent in children treated with the implant as
compared with traditional monthly injections.
In conclusion, the histrelin implant appears to be safe,
well-tolerated,and eﬀectivewhenanew implant is placedfor
a second year of therapy. Long-term prospective follow-up
of treated patients will be essential in order to conﬁrm these
results.
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